Drug resistant malaria is increasing worldwide, with over 70% of malignant malaria parasites developing varying degrees of resistance to existing antimalarial drugs such as chloroquine, chlorophenoquine, chloroguanidine, pyrimidine, and methylchloroquine and their combinations during use. In addition, toxic side effects such as aminophenol quine, methylchloroquine, and their compounds are also relatively serious, directly affecting the treatment of 103 million malaria patients and 264 million malaria parasite carriers worldwide every year.
Artemether (C18H28O5) and benflumetol (C30H32CI3NO) are two newly developed antimalarial drugs with different structures and effects in recent years. These two drugs are usually treated with a single drug. The characteristic of artemether's action is to kill malaria parasites quickly, but not completely. After treatment, the residual parasite in the patient's blood has a high rate of re ignition. On the contrary, benflumetol is more thorough in killing insects, has a high cure rate, but has a slow effect. However, the commonality between the two is that it has a significant therapeutic effect on drug-resistant malignant malaria.
The purpose of the present invention is to provide an antimalarial drug compound artemether, which is based on the principle of synergistic and complementary effects between drugs. Through animal experimental research, the type of action between drugs is determined, and the composition of the compound is searched to achieve the goal of leveraging strengths and avoiding weaknesses. It not only leverages the advantages of artemether's quick acting effect, but also fully utilizes the characteristics of Benflumetol's thorough insecticidal and high cure rate. So far, there are no similar anti malaria compound products domestically and internationally.